Novartis highlights depth of immunology pipeline with novel data at key upcoming international congresses
- Pivotal results for efficacy and safety of Cosentyx® (secukinumab) in hidradenitis suppurativa from Phase III SUNSHINE and SUNRISE trials to be debuted as late-breaker at European Academy of Dermatology and Venereology (EADV) Congress
- Phase IIb data on remibrutinib (LOU064), an oral Bruton’s tyrosine kinase inhibitor, for people living with chronic spontaneous urticaria to be highlighted at EADV
- Results of analysis at Week 52 from Phase IIb trial of ianalumab (VAY736), a dual mode of action B-cell activating factor receptor inhibitor in Sjögren’s syndrome, to be unveiled at International Symposium on Sjögren’s Syndrome
- Total of 37 abstracts across both meetings will be presented, reflecting Novartis ambition to improve the lives of those affected by a range of immunological diseases
Basel, September 2, 2022 — Novartis today announced it will showcase data from its leading immunology portfolio and emerging pipeline at the upcoming 31st European Academy of Dermatology and Venereology (EADV) Congress and the 15th International Symposium on Sjögren’s Syndrome (ISSS), both occurring September 7–10, 2022. A total of 37 abstracts will be shared across both meetings, spanning hidradenitis suppurativa (HS), chronic spontaneous urticaria (CSU), Sjögren’s syndrome, axial spondyloarthritis, and psoriasis.
“These data – including late-breaking results from our pivotal trials for Cosentyx® in hidradenitis suppurativa – demonstrate both the strength of our portfolio, and our commitment to pioneering the medicines of tomorrow in immunology,” said Angelika Jahreis M.D., Ph.D., FAAD, Global Head Development Unit Immunology and Clinical Development Excellence, Novartis. “We are focusing our development efforts on immunological diseases with significant unmet need, and hope that we will soon be able to provide more treatment options to patients to manage their conditions.”
The Novartis ambition is to reduce the suffering from immunological conditions, which affect up to 4.5% of the world’s population and can have a significant impact on quality of life1. In addition to its comprehensive portfolio of innovative therapy options, Novartis is exploring potential biologic and oral treatments with various mechanisms of action in HS, developing medicines that could help those living with CSU achieve complete symptom control, and advancing research in Sjögren’s syndrome, for which there are currently no disease-modifying treatments available2,3.
To assess and elevate the patient perspective at every stage of its clinical research, Novartis will also share the latest findings from a number of patient-based initiatives at EADV, including the global Psoriasis and Beyond study exploring the impact of psoriatic disease on mental health. Results from a comprehensive social media monitoring program to help illuminate the significant unmet needs of people living with HS will also be presented.
Highlights at ISSS
Medicine | Disease area | Abstract title | Abstract number/ presentation details |
Ianalumab (VAY736) | Sjögren’s syndrome | Ianalumab (VAY736) Safety and Efficacy in Patients with Sjögren’s Syndrome: 52 Week Results from a Randomized, Placebo-controlled, Phase 2b Dose-ranging Trial | Abstract ID119/ oral presentation/ September 9, 17:44–17:51 |
Highlights at EADV
Medicine | Disease area | Abstract title | Abstract number/ presentation details |
Cosentyx | Hidradenitis suppurativa | Secukinumab in Moderate to Severe Hidradenitis Suppurativa: Primary Endpoint Analysis from the SUNSHINE and SUNRISE Phase 3 Trials | Abstract LB3549/ oral presentation/ September 10, 2022, 08:30–08:45 Late-breaking presentation |
Cosentyx | Hidradenitis suppurativa | Baseline Characteristics and Subtype Clusters in Hidradenitis Suppurativa: Exploratory Analysis of SUNSHINE and SUNRISE Studies | Abstract P0040/ poster presentation/ September 7, 2022, 07:00 |
Cosentyx | Psoriasis | Secukinumab Demonstrates Superiority over Narrow-Band Ultraviolet B Phototherapy in New-Onset Moderate to Severe Plaque Psoriasis Patients: Week 52 Results from the STEPIn Study | Abstract P1518/ poster presentation/ September 7, 2022, 07:00 |
Cosentyx | Psoriasis | Secukinumab Treatment Interruption Does Not Impact Effectiveness in Patients with Moderate to Severe Plaque Psoriasis: Results from an Interim Analysis of the SERENA Study | Abstract P1520/ poster presentation/ September 7, 2022, 07:00 |
Cosentyx | Spondyloarthritis | Humoral Immunogenicity to Second and Third Doses of COVID-19 Vaccine BNT162b2 in Patients with Spondyloarthritis Receiving Secukinumab: A Prospective Study | Abstract P0584/ poster presentation/ September 7, 2022, 07:00 |
Remibrutinib (LOU064) | Chronic spontaneous urticaria | Remibrutinib Demonstrates Faster Time to Complete Urticaria Control in Patients with Chronic Spontaneous Urticaria Compared with Placebo | Abstract P1726/ poster presentation/ September 7, 2022, 07:00 |
Remibrutinib (LOU064) | Chronic spontaneous urticaria | Long-Term Safety and Tolerability of Remibrutinib (LOU064) in Phase 2b Study in Chronic Spontaneous Urticaria Patients | Abstract P1722/ poster presentation/ September 7, 2022, 07:00 |
Patient study | Chronic urticaria | Urticaria Voices: Design of a Real-World Study on the Burden of Chronic Urticaria from Patients’ and Physicians’ Perspectives | Abstract P1739/ poster presentation/ September 7, 2022, 07:00 |
Patient study | Psoriatic disease | Impact of Psoriatic Disease on Mental Health: Results from the Global Psoriasis and Beyond Study | Abstract FC06.08/ oral presentation/ September 10, 15:25–15:35 |
Patient study | Hidradenitis suppurativa | Understanding the Real-World Patient Journey and Unmet Needs of Patients with Hidradenitis Suppurativa through Social Media Monitoring | Abstract FC08.02/ oral presentation/ September 10, 16:10–16:20 |
Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “seek,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
About Novartis in Immunology
Novartis aims to improve outcomes and enhance the lives of those affected by painful and debilitating immunological conditions. As a result, we have already helped transform the standard of care for children and adults suffering from conditions such as psoriatic disease and axial spondyloarthritis with Cosentyx®, chronic urticaria with Xolair®, and a number of rare autoinflammatory diseases with Ilaris®. We continue to focus on discovering and delivering innovative medicines for complex, less-explored immunological diseases where there is significant unmet need, such as hidradenitis suppurativa and Sjögren’s syndrome, lupus and osteoarthritis.
About Novartis
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world. Find out more at https://www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews
For Novartis multimedia content, please visit https://www.novartis.com/news/media-library.
For questions about the site or required registration, please contact media.relations@novartis.com.
References
1. Scientific American. The Terrible Toll of 76 Autoimmune Diseases [online]. Available from: https://www.scientificamerican.com/article/the-terrible-toll-of-76-autoimmune-diseases/ [Last accessed: August 2022].
2. Sjögren's Foundation. Understanding Sjögren's - Symptoms [online]. Available from: https://www.sjogrens.org/understanding-sjogrens/symptoms [Last accessed: August 2022].
3. NHS. Treatment - Sjögren's syndrome [online]. Available from: https://www.nhs.uk/conditions/sjogrens-syndrome/treatment/ [Last accessed: August 2022].
# # #
Novartis Media Relations
E-mail: media.relations@novartis.com
Michael Meo Novartis US External Communications +1 862 274 5414 (direct) michael.meo@novartis.com Julie Masow Novartis US External Communications +1 862 579 8456 julie.masow@novartis.com | Rachel Fink-Thoma Novartis Pharmaceuticals Communications +41 613 248 245 (direct) rachel.fink@novartis.com |
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com
Central | North America | ||
Samir Shah | +41 61 324 7944 | Sloan Simpson | +1 862 345 4440 |
Nicole Zinsli-Somm | +41 61 324 3809 | Alina Levchuk | +1 862 778 3372 |
Isabella Zinck | +41 61 324 7188 | Parag Mahanti | +1 973-876-4912 |
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Correction to Company announcement – No. 23 / 202419.4.2024 22:20:51 CEST | Press release
Correction to Company announcement – No. 23 / 2024 Copenhagen, Denmark, April 19, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has a correction to company announcement No. 23 /2024, April 19, 2024 - regarding transactions in Zealand’s shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons it was reported that member of the management, Henriette Wennicke, was allocated a total of 8,008 restricted stock units with a total value of DKK 9,577,568.00. The correct number was a total of 8,008 restricted stock units with a total value of DKK 4,788,784.00. Please see the attached file(s). # # # About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10
Nokia Corporation: Repurchase of own shares on 19.04.202419.4.2024 21:30:00 CEST | Press release
Nokia Corporation Stock Exchange Release 19 April 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 19.04.2024 Espoo, Finland – On 19 April 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL430,8933.30CEUX--BATE--AQEU--TQEX--Total430,8933.30 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of
RomReal 2023 Annual report including accounts and Audit statement19.4.2024 21:00:00 CEST | Press release
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachments ANNUAL REPORT RomReal and Financial statements 2023Independent auditors report RomReal 2023
Landsbankinn hf.: Results of the 2024 AGM of Landsbankinn19.4.2024 20:48:08 CEST | Press release
The annual general meeting (AGM) of Landsbankinn, held on 19 April 2024, agreed to pay a dividend amounting to ISK 16,535 million to shareholders. The dividend is equivalent to 50% of 2023 profits. The dividend will be paid in two instalments, firstly on 24 April 2024 and secondly on 16 October 2024. As a result, total dividend paid by the Bank in 2013-2024 amounts to ISK 191.7 billion. At the AGM, held in Reykjastræti 6, Helga Björk Eiríksdóttir, Chairman of the Board of Directors, delivered the report from the Board for 2023. Lilja Björk Einarsdóttir, CEO, spoke of the Bank’s operation, strategy and activities in the past operating year. The annual financial statement for the past operating year was approved, as was the proposed Remuneration Policy and remuneration to Directors of the Board. The AGM elected the Auditor General (Ríkisendurskoðun) as auditor of Landsbankinn hf. for the 2024 operating year. The Auditor General, in accordance with an authorisation to outsource tasks, and
SKEL fjárfestingafélag hf.: Styrkás finalizes the purchase of Stólpi Gámar ehf. and affiliated companies.19.4.2024 19:20:57 CEST | Press release
Reference is made to the announcement dated 31 January 2024, regarding Styrkás hf., a company 69.64% owned by SKEL fjárfestingafélag hf., signing a purchase agreement to acquire 100% of the shares in six subsidiaries of Máttarstólpi ehf. The purchase agreement was subject to the approval of the Competition Authority. The transaction was finalized today with payment of purchase price and delivering of shares in the following companies: - Stólpi Gámar ehf., id. 460121-1590, Klettagörðum 5, 104 Reykjavík: - Stólpi Smiðja ehf., id. 460121-1750, Klettagörðum 5, 104 Reykjavík; - Klettskjól ehf., id. 460121-0510, Klettagörðum 5, 104 Reykjavík; - Stólpi ehf., 460121-0430, Klettagörðum 5, 104 Reykjavík; - Tjónaþjónustan ehf., id. 460121-1670, Klettagörðum 5, 104 Reykjavík; - Alkul ehf., id. 491020-0830, Haukdælabraut 48, 113 Reykjavík. collectively referred to as "the sold companies". These companies will continue to be operated on a consolidated basis. The Enterprise value of the sold companie